Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGENERATE-PD: AAV2-GDNF in Moderate Stage Parkinson's Disease
NCT06285643Phase 2Active, not recruiting
- Sponsor
- AskBio
- Start
- Jun 2024
- Primary completion
- Aug 2028
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 4
01
Overview
A Phase 2 trial of ametefgene parvec in Parkinson's disease (PD), sponsored by AskBio. Started Jun 2024; status: active, not recruiting.
02
Drugs
ametefgene parvec
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06285643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06285643.